Summary
12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altounyan, R.E.C.: Measurements of factors influencing bronchoconstriction. Proc. roy. Soc. Med.59 (Suppl.), 56–62 (1969)
Atkinson, J.M., Rand, M.J.: Mutual suppression of cardiovascular effects of some β-adrenoreceptor agonists in the cat. J. Pharm. Pharmacol.20, 916–922 (1968)
Balazs, T., Ohtake, S., Noble, J.F.: The development of resistance to the ischemic cardiopathic effect of isoproterenol. Toxicol. appl. Pharmacol.21, 200–213 (1972)
Blackwell, E.W., Conolly, M.E., Davies, D.S., Dollery, C.T., George, C.F.: Resistance to β-adrenoceptor stimulants and death from bronchial asthma. Brit. J. Pharmacol.41, 410 P (1971)
Butterworth, K.R.: The β-adrenergic blocking and pressor actions of isoprenaline in the cat. Brit. J. Pharmacol.21, 378–392 (1963)
Butterworth, K.R.: The pressor response in the cat to isoprenaline following β-adrenergic blockade. Int. J. Neuropharmacol.3, 23–25 (1964)
Champy, C., Gley, E.: Sur la toxicité des extraits de corps jaune. Immunisation rapide consécutive à l'injection de petites doses de ces extraits (tachyphylaxie). C.R. Soc. Biol. (Paris),71, 159 (1911)
Conolly, M.E., Davies, D.S., Dollery, C.T., George, C.F.: Resistance to β-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Brit. J. Pharmacol.43, 389–402 (1971)
Coret, I.A., van Dyke, H.B.: The altered blood-pressure response after adrenolytic drugs and large doses of sympathomimetic amines. J. Pharmacol. exp. Ther.95, 415–420 (1949)
Curtis, J.K., Liska, A.P., Rasmussen, H.K., Cree, E.M.: The bronchospastic component in patients with chronic bronchitis and emphysema. J. Amer. med. Ass.197, 693–696 (1966)
Feinmann, L., Newell, D.J.: Isoprenaline in the treatment of chronic bronchitis. A controlled trial of different methods of administration. Brit. J. Dis. Chest.57, 140–146 (1963)
Flecker, A.: Zur Wirkung von Aludrin auf das Atem- und Kreislaufzentrum und dessen Dosierung. Wien. klin. Wschr.74, 13–15 (1962)
Fleisch, J.H., Titus, E.: The prevention of isoproterenol desensitization and isoproterenol reversal. J. Pharmacol. exp. Ther.181, 425–433 (1972)
George, C.F., Conolly, M.E., Fenyvesi, T., Briant, R., Dollery, C.T.: Intravenously administered isoproterenol sulfate dose-response curves in man. Arch. intern. Med.130, 361–364 (1972)
Hume, K.M., Gandevia, B.: Forced expiratory volume before and after isoprenaline. Thorax12, 276–278 (1957)
Hume, K.M., Rhys-Jones, E.: The response to bronchodilators in intrinsic asthma. Quart. J. Med.30, 189–199 (1961)
Kingsley, P.J., Littlejohns, D.W., Prichard, B.N.C.: Isoprenaline-induced tachycardia in man. Brit. J. Pharmacol.46, 539 P-540 P (1972)
Paterson, J.W., Conolly, M.E., Davies, D.S., Dollery, C.T.: Isoprenaline resistance and the use of pressurised aerosols in asthma. Lancet1968 II, 426–429
Paterson, J.W.: Human pharmacology: comparison of intravenous isoprenaline and salbutamol in asthmatic patients. Postgrad. med. J. (Suppl.) 38–39 (1971)
Pun, L.Q., McCulloch, M.W., Rand, M.J.: Bronchodilator effects of sympathomimetic amines given singly and in combination. Europ. J. Pharmacol.2, 140–149 (1971)
Shenfield, G.M., Paterson, J.W.: Clinical assessment of bronchodilator drugs delivered by aerosol. Thorax28, 124–128 (1973)
Svedmyr, N., Malmberg, R., Thiringer, G.: The effect of a new beta2-receptor stimulary agent (rimiterol, R 798) in patients with chronic obstructive lung disease. Scand. J. resp. Dis.53, 302–313 (1972)
Svedmyr, N., Thiringer, G.: The effects of salbutamol and isoprenaline on beta-receptors in patients with chronic obstructive lung disease. Postgrad. med. J.1971, 44–46 (1971)
Tendis, N.: Über die Kreislaufwirkung einiger adrenalinähnlicher Substanzen im Vergleich zum Ausgangsstoff Adrenalin. Inaug. Diss. Mainz 1949
Thiringer, G., Bergh, N.P., Svedmyr, N.: A comparative study of the effects of isoetharine and some other adrenergic beta-stimulators in chronic obstructive lung disease. Scand. J. resp. Dis.52, 183–191 (1971)
Ulmer, W.T.: Was ist gesichert in der Behandlung der obstruktiven Atemwegserkrankungen? Internist13, 507–513 (1972)
Valette, G., Cohen, Y., Bralet, J., Jacquot, C.: Tolérance et tachyphylaxie à la lumière d'expériences effectuées sur l'ephedrine. Proc. Europ. Soc. Study Drug Toxicity12, 37–49 (1971)
Warrell, D.A., Robertson, D.G., Newton Howes, J., Conolly, M.E., Paterson, J.W., Beilin, L.J., Dollery, C.T.: Comparison of cardiorespiratory effects of isoprenaline and salbutamol in patients with bronchial asthma. Brit. med. J.1970 I, 65–70
Wettengel, R., Fabel, H.: Placebovergleich mit Berotec-Dosier-Aerosol und ansteigenden Dosierungen. Int. J. clin. Pharmacol., Beiheft 4 Berotec 96–99 (1971)
Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions. A report of the conclusion of a Ciba Guest Symposium. Thorax 14, 286–299 (1959)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lichterfeld, A., Löllgen, H. Investigation into isoprenaline resistance in patients with obstructive lung disease. Eur J Clin Pharmacol 7, 347–351 (1974). https://doi.org/10.1007/BF00558204
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558204